Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
14.70 -0.19 -1.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 14.71 -1.21%
After-hours 14.64 -0.41%
18.6214.5714.702026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AUPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -8.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 5.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation C+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 6.4x Better than 94%
Forward P/E 19.9x Better than 37%
Price / Sales 6.6x Better than 16%
P/E vs own 5-yr range 67th pctl Better than 41%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.5% Better than 96%
Operating margin 37.6% Better than 94%
Net margin 101.5% Better than 100%
Return on equity 59.9% Better than 95%
Return on invested capital 50.4% Better than 99%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -11.7% Better than 46%
6-month return -3.4% Better than 49%
12-month return (ex latest month) 10.5% Better than 46%
Distance below 52-week high 23.6% Better than 53%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.2x Better than 87%
Debt to assets 10.0% Better than 70%
Interest coverage 27.4x Better than 86%
Free cash flow / net income 47.1% Better than 13%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 29.3% Better than 48%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.55%
1M -12.19%
3M -14.88%
6M -7.55%
YTD -7.84%
1Y -2.91%
3Y +59.09%
5Y -48.37%

Key statistics

Price & volume

Prev close
14.89
Open
14.69
Day range
14.63 - 14.97
Avg price
14.76
Volume
1.34M
Turnover
19.80M
Amplitude
2.26%
52-week range
13.52 - 19.25

Valuation

P/E
7.10
P/E (TTM)
6.45
P/B
3.00
EPS
2.07
Net profit
277.38M
Net assets
657.53M

Share structure

Market cap
1.97B
Float cap
1.91B
Shares out
134.00M
Float shares
130.11M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 21% of range
13.52 19.25

23.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.24M net over the window

Short interest

Shares short
7.14M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals last traded at 14.70. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Aurinia Pharmaceuticals's market cap?

About 1.97B.

What is the P/E ratio of Aurinia Pharmaceuticals?

The trailing twelve-month P/E is 6.45, above its own 5-year average of 2.84 — toward the top of its historical range (67.38% percentile). See the Valuation tab for the full history.

Does Aurinia Pharmaceuticals pay a dividend?

Aurinia Pharmaceuticals does not currently pay a regular dividend.

Is Aurinia Pharmaceuticals a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 19.00, which implies 29.3% upside from the current price. This is not investment advice.

What is Aurinia Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Aurinia Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Aurinia Pharmaceuticals discussion 0 comments

Add a comment